Key takeaways
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) and Complera (emtricitabine/rilpivirine/tenofovir) are both single-tablet regimens used for the treatment of HIV. Stribild includes an integrase inhibitor (elvitegravir) and a booster (cobicistat), while Complera contains a non-nucleoside reverse transcriptase inhibitor (NNRTI) (rilpivirine). Both medications must be taken with food to ensure proper absorption, but Stribild can be taken with any meal, whereas Complera should be taken with at least 400 calories. Stribild is not recommended for people with kidney or liver problems, and Complera, on the other hand, is not recommended for people with high viral loads. Both medications have many drug interactions and can cause kidney and bone problems, but Complera is also associated with mood changes and depression. Stribild is not a preferred option during pregnancy, while Complera can be used during pregnancy but not during breastfeeding.
